[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4QA2dUaKR7LZUc-avkdHsbaFdNgmwbSsrzBBTbB1QNg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"HealthPartners Institute",[4],164,false,25,2,273946,6,130,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Type 2 Diabetes",12,{"name":18,"count":16},"Hypertension",{"name":20,"count":21},"Diabetes",8,{"name":23,"count":11},"Obesity",{"name":25,"count":26},"Breast Cancer",5,{"name":28,"count":26},"Dementia",{"name":30,"count":26},"Diabetes Mellitus",{"name":32,"count":26},"Hyperlipidemia",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05777590","Comparison of ICG Microangiography and Conventional Angiography in Severe Frostbite","2025-02-01","Indocyanine Green Angiogram",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07384052","Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury","2026-08","Regular Insulin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06605430","Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","2026-09","Medical Cannabis",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07354919","Axelopran for Advanced Cancer in Patients Receiving Opioids","2027-11-01","axelopran",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06285448","Feasibility of Lecanemab Registry and Clinical Outcome Measures","2027-12-31","Lecanemab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07325201","Reducing Risk of Diabetic Ketoacidosis in Type 1 Diabetes and Kidney Disease Using Continuous Ketone Monitoring","2028-05","Sotagliflozin initiation",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,99,123,148,168,190,213,240,258,285,303,327,354,380,407,434,452,478,496,525,549,572,618,640,665,692,716,741,766,793,811,846,868,895,913,938,972,990,1014],{"intervention":53,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":93,"PHASE4":95,"NA":97},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":73,"soonestReadout":52},[82],{"nctId":50,"briefTitle":51,"status":83,"phases":84,"primaryCompletion":52,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":92},"RECRUITING",[67],"2028-11-01","2026-04-27",34,[25,89,90,91],"Lung Cancer","Pancreas Cancer","Prostate Cancer",[53],{"trials":94,"activeCount":77},[],{"trials":96,"activeCount":77},[],{"trials":98,"activeCount":77},[],{"intervention":48,"totalTrials":73,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":117,"PHASE4":119,"NA":121},{"trials":102,"activeCount":77},[],{"trials":104,"activeCount":77},[],{"trials":106,"activeCount":73,"soonestReadout":47},[107],{"nctId":45,"briefTitle":46,"status":83,"phases":108,"primaryCompletion":47,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":116},[67],"2026-12","2024-09-16",64,[113,114,115],"Pancreatic Cancer Non-resectable","Pancreatic Cancer Metastatic","Colorectal Cancer Metastatic",[48],{"trials":118,"activeCount":77},[],{"trials":120,"activeCount":77},[],{"trials":122,"activeCount":77},[],{"intervention":63,"totalTrials":73,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":142,"PHASE4":144,"NA":146},{"trials":126,"activeCount":77},[],{"trials":128,"activeCount":77},[],{"trials":130,"activeCount":73,"soonestReadout":62},[131],{"nctId":60,"briefTitle":61,"status":132,"phases":133,"primaryCompletion":62,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":141},"NOT_YET_RECRUITING",[67],"2028-08","2026-06",80,[138,139,140],"Type 1 Diabetes Mellitus","Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)","Chronic Kidney Disease",[63],{"trials":143,"activeCount":77},[],{"trials":145,"activeCount":77},[],{"trials":147,"activeCount":77},[],{"intervention":43,"totalTrials":73,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":151,"activeCount":77},[],{"trials":153,"activeCount":73,"soonestReadout":42},[154],{"nctId":40,"briefTitle":41,"status":83,"phases":155,"primaryCompletion":42,"completion":47,"start":156,"enrollment":16,"conditions":157,"interventions":159},[66],"2026-02-20",[158],"Spinal Cord Injury",[43],{"trials":161,"activeCount":77},[],{"trials":163,"activeCount":77},[],{"trials":165,"activeCount":77},[],{"trials":167,"activeCount":77},[],{"intervention":38,"totalTrials":73,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":180},{"trials":171,"activeCount":77},[],{"trials":173,"activeCount":77},[],{"trials":175,"activeCount":77},[],{"trials":177,"activeCount":77},[],{"trials":179,"activeCount":77},[],{"trials":181,"activeCount":73,"soonestReadout":37},[182],{"nctId":35,"briefTitle":36,"status":183,"phases":184,"primaryCompletion":37,"completion":185,"start":186,"enrollment":21,"conditions":187,"interventions":189},"ACTIVE_NOT_RECRUITING",[],"2026-05-30","2023-02-03",[188],"Frostbite",[38],{"intervention":58,"totalTrials":73,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":193,"activeCount":77},[],{"trials":195,"activeCount":77},[],{"trials":197,"activeCount":77},[],{"trials":199,"activeCount":77},[],{"trials":201,"activeCount":77},[],{"trials":203,"activeCount":73,"soonestReadout":57},[204],{"nctId":55,"briefTitle":56,"status":205,"phases":206,"primaryCompletion":57,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"ENROLLING_BY_INVITATION",[],"2028-06-30","2024-01-02",20,[211],"Alzheimer Disease",[58],{"intervention":214,"totalTrials":73,"cells":215},"Ketamine",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":238},{"trials":217,"activeCount":77},[],{"trials":219,"activeCount":77},[],{"trials":221,"activeCount":77},[],{"trials":223,"activeCount":77},[],{"trials":225,"activeCount":77},[226],{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT01951963","Sub-dissociative Ketamine for the Management of Acute Pediatric Pain","COMPLETED",[69],"2015-06","2012-12",77,[235],"Pain",[214,237],"Morphine",{"trials":239,"activeCount":77},[],{"intervention":237,"totalTrials":73,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":256},{"trials":243,"activeCount":77},[],{"trials":245,"activeCount":77},[],{"trials":247,"activeCount":77},[],{"trials":249,"activeCount":77},[],{"trials":251,"activeCount":77},[252],{"nctId":227,"briefTitle":228,"status":229,"phases":253,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":254,"interventions":255},[69],[235],[214,237],{"trials":257,"activeCount":77},[],{"intervention":259,"totalTrials":73,"cells":260},"Hydroxyzine",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":283},{"trials":262,"activeCount":77},[],{"trials":264,"activeCount":77},[],{"trials":266,"activeCount":77},[],{"trials":268,"activeCount":77},[],{"trials":270,"activeCount":77},[271],{"nctId":272,"briefTitle":273,"status":274,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":77,"conditions":278,"interventions":281},"NCT01372670","Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder","WITHDRAWN",[69],"2013-04","2012-01",[279,280],"Anxiety in Those Patients With Anorexia Nervosa","Eating Disorder Not Otherwise Specified, BMI (\u003C=18)",[259,282],"hydroxyzine HCL",{"trials":284,"activeCount":77},[],{"intervention":282,"totalTrials":73,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":301},{"trials":288,"activeCount":77},[],{"trials":290,"activeCount":77},[],{"trials":292,"activeCount":77},[],{"trials":294,"activeCount":77},[],{"trials":296,"activeCount":77},[297],{"nctId":272,"briefTitle":273,"status":274,"phases":298,"primaryCompletion":276,"completion":276,"start":277,"enrollment":77,"conditions":299,"interventions":300},[69],[279,280],[259,282],{"trials":302,"activeCount":77},[],{"intervention":304,"totalTrials":73,"cells":305},"Nitrostat 0.4Mg Sublingual",{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":325},{"trials":307,"activeCount":77},[],{"trials":309,"activeCount":77},[],{"trials":311,"activeCount":77},[],{"trials":313,"activeCount":77},[],{"trials":315,"activeCount":77},[316],{"nctId":317,"briefTitle":318,"status":229,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":209,"conditions":322,"interventions":324},"NCT03305848","Esophageal Food Impaction",[69],"2019-04-04","2017-08-25",[323],"Esophageal Food Bolus Obstruction",[304],{"trials":326,"activeCount":77},[],{"intervention":328,"totalTrials":73,"cells":329},"mirabegron",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":352},{"trials":331,"activeCount":77},[],{"trials":333,"activeCount":77},[],{"trials":335,"activeCount":77},[],{"trials":337,"activeCount":77},[],{"trials":339,"activeCount":77},[340],{"nctId":341,"briefTitle":342,"status":229,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":351},"NCT02536976","Mirabegron in Parkinson Disease and Impaired Cognition",[69],"2018-08-01","2015-12",7,[348,349,350],"Parkinson Disease","Overactive Bladder","Impaired Cognition",[328],{"trials":353,"activeCount":77},[],{"intervention":355,"totalTrials":73,"cells":356},"Lidocaine",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":378},{"trials":358,"activeCount":77},[],{"trials":360,"activeCount":77},[],{"trials":362,"activeCount":77},[],{"trials":364,"activeCount":77},[],{"trials":366,"activeCount":77},[367],{"nctId":368,"briefTitle":369,"status":229,"phases":370,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":377},"NCT02059902","Continuous Lidocaine Infusion for Management of Perioperative Burn Pain",[69],"2014-09","2015-02","2012-09",36,[376],"Thermal Burns",[355],{"trials":379,"activeCount":77},[],{"intervention":381,"totalTrials":73,"cells":382},"L-carnitine L-tartrate",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":405},{"trials":384,"activeCount":77},[],{"trials":386,"activeCount":77},[],{"trials":388,"activeCount":77},[],{"trials":390,"activeCount":77},[],{"trials":392,"activeCount":77},[393],{"nctId":394,"briefTitle":395,"status":396,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":9,"conditions":401,"interventions":404},"NCT00754767","L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer","TERMINATED",[69],"2008-04-02","2008-05-02","2007-01-02",[25,402,403],"Chemotherapeutic Agent Toxicity","Neurotoxicity",[381],{"trials":406,"activeCount":77},[],{"intervention":408,"totalTrials":73,"cells":409},"Standard of Care as per attending physician",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":432},{"trials":411,"activeCount":77},[],{"trials":413,"activeCount":77},[],{"trials":415,"activeCount":77},[],{"trials":417,"activeCount":77},[],{"trials":419,"activeCount":77},[420],{"nctId":421,"briefTitle":422,"status":229,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT03066622","Olanzapine for Acute Headaches",[69],"2018-05-17","2018-05-20","2016-07",122,[429],"Headache",[408,431],"5mg rapidly dissolving olanzapine",{"trials":433,"activeCount":77},[],{"intervention":431,"totalTrials":73,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":450},{"trials":437,"activeCount":77},[],{"trials":439,"activeCount":77},[],{"trials":441,"activeCount":77},[],{"trials":443,"activeCount":77},[],{"trials":445,"activeCount":77},[446],{"nctId":421,"briefTitle":422,"status":229,"phases":447,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":448,"interventions":449},[69],[429],[408,431],{"trials":451,"activeCount":77},[],{"intervention":453,"totalTrials":73,"cells":454},"NPH insulin plus Complete Insulin Orders",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":476},{"trials":456,"activeCount":77},[],{"trials":458,"activeCount":77},[],{"trials":460,"activeCount":77},[],{"trials":462,"activeCount":77},[],{"trials":464,"activeCount":77},[465],{"nctId":466,"briefTitle":467,"status":229,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":474},"NCT01184014","Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia",[69],"2012-08","2010-08",72,[473],"Hyperglycemia",[453,475],"Complete Insulin Orders",{"trials":477,"activeCount":77},[],{"intervention":475,"totalTrials":73,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":77},[],{"trials":483,"activeCount":77},[],{"trials":485,"activeCount":77},[],{"trials":487,"activeCount":77},[],{"trials":489,"activeCount":77},[490],{"nctId":466,"briefTitle":467,"status":229,"phases":491,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":492,"interventions":493},[69],[473],[453,475],{"trials":495,"activeCount":77},[],{"intervention":497,"totalTrials":73,"cells":498},"4-factor prothrombin complex concentrate",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":523},{"trials":500,"activeCount":77},[],{"trials":502,"activeCount":77},[],{"trials":504,"activeCount":77},[],{"trials":506,"activeCount":77},[],{"trials":508,"activeCount":77},[509],{"nctId":510,"briefTitle":511,"status":229,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":522},"NCT03064035","Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal",[69],"2019-04-17","2019-04-24","2017-04-05",79,[518,519,520,521],"Acute Bleeding on Long-Term Anticoagulation Therapy","Hemorrhage","Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)","Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation",[497],{"trials":524,"activeCount":77},[],{"intervention":526,"totalTrials":73,"cells":527},"colesevelam HCl",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":545,"NA":547},{"trials":529,"activeCount":77},[],{"trials":531,"activeCount":77},[],{"trials":533,"activeCount":77},[],{"trials":535,"activeCount":77},[536],{"nctId":537,"briefTitle":538,"status":229,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT00993824","Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes",[67,68],"2011-09","2009-09",21,[15],[526],{"trials":546,"activeCount":77},[],{"trials":548,"activeCount":77},[],{"intervention":550,"totalTrials":73,"cells":551},"Zoledronic acid",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":568,"NA":570},{"trials":553,"activeCount":77},[],{"trials":555,"activeCount":77},[],{"trials":557,"activeCount":77},[],{"trials":559,"activeCount":77},[560],{"nctId":561,"briefTitle":562,"status":229,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":471,"conditions":566,"interventions":567},"NCT00202059","Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer",[68],"2007-09","2003-06",[25],[550],{"trials":569,"activeCount":77},[],{"trials":571,"activeCount":77},[],{"intervention":573,"totalTrials":574,"cells":575},"Insulin glulisine",3,{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":590,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":577,"activeCount":77},[],{"trials":579,"activeCount":77},[580],{"nctId":581,"briefTitle":582,"status":229,"phases":583,"primaryCompletion":584,"completion":584,"start":585,"enrollment":16,"conditions":586,"interventions":588},"NCT02432716","Investigation of the Safety of Intranasal Glulisine in Down Syndrome",[66],"2018-10-18","2015-04",[587],"Down Syndrome",[573,589],"Saline",{"trials":591,"activeCount":77},[592,600],{"nctId":593,"briefTitle":594,"status":229,"phases":595,"primaryCompletion":596,"completion":596,"start":540,"enrollment":16,"conditions":597,"interventions":599},"NCT01436045","Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.",[67],"2013-06",[598],"Alzheimer's Disease",[573,589],{"nctId":601,"briefTitle":602,"status":396,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":611},"NCT02503501","Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease",[67],"2019-02-11","2019-02-15","2015-09-28",49,[609,610],"Mild Cognitive Impairment","Alzheimer's Disease (AD)",[573],{"trials":613,"activeCount":77},[],{"trials":615,"activeCount":77},[],{"trials":617,"activeCount":77},[],{"intervention":589,"totalTrials":9,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":628,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":621,"activeCount":77},[],{"trials":623,"activeCount":77},[624],{"nctId":581,"briefTitle":582,"status":229,"phases":625,"primaryCompletion":584,"completion":584,"start":585,"enrollment":16,"conditions":626,"interventions":627},[66],[587],[573,589],{"trials":629,"activeCount":77},[630],{"nctId":593,"briefTitle":594,"status":229,"phases":631,"primaryCompletion":596,"completion":596,"start":540,"enrollment":16,"conditions":632,"interventions":633},[67],[598],[573,589],{"trials":635,"activeCount":77},[],{"trials":637,"activeCount":77},[],{"trials":639,"activeCount":77},[],{"intervention":641,"totalTrials":73,"cells":642},"Nivolumab",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":659,"PHASE4":661,"NA":663},{"trials":644,"activeCount":77},[],{"trials":646,"activeCount":77},[],{"trials":648,"activeCount":77},[649],{"nctId":650,"briefTitle":651,"status":274,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":77,"conditions":656,"interventions":658},"NCT03927248","PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer",[66,67],"2021-09","2021-12","2020-09",[657],"Metastatic Renal Cell Carcinoma",[641],{"trials":660,"activeCount":77},[],{"trials":662,"activeCount":77},[],{"trials":664,"activeCount":77},[],{"intervention":666,"totalTrials":73,"cells":667},"Vitamin D3",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":669,"activeCount":77},[],{"trials":671,"activeCount":77},[],{"trials":673,"activeCount":77},[674],{"nctId":675,"briefTitle":676,"status":229,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":685},"NCT01509079","Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors",[67],"2014-10","2015-03","2012-03",116,[683,684],"Muscle Pain","Joint Pain",[666,666],{"trials":687,"activeCount":77},[],{"trials":689,"activeCount":77},[],{"trials":691,"activeCount":77},[],{"intervention":693,"totalTrials":73,"cells":694},"Regular Novolin R",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":696,"activeCount":77},[],{"trials":698,"activeCount":77},[],{"trials":700,"activeCount":77},[701],{"nctId":702,"briefTitle":703,"status":229,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":709},"NCT04251585","Intranasal Insulin in Parkinson's Disease",[67],"2024-08-27","2020-02-04",31,[348],[693],{"trials":711,"activeCount":77},[],{"trials":713,"activeCount":77},[],{"trials":715,"activeCount":77},[],{"intervention":717,"totalTrials":73,"cells":718},"Novolin-R insulin",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":720,"activeCount":77},[],{"trials":722,"activeCount":77},[],{"trials":724,"activeCount":77},[725],{"nctId":726,"briefTitle":727,"status":396,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":574,"conditions":732,"interventions":734},"NCT04115384","Intranasal Insulin in Frontotemporal Dementia (FTD)",[67],"2020-02-26","2023-05-15","2019-09-09",[733],"Frontotemporal Dementia, Behavioral Variant",[717],{"trials":736,"activeCount":77},[],{"trials":738,"activeCount":77},[],{"trials":740,"activeCount":77},[],{"intervention":742,"totalTrials":73,"cells":743},"Regular insulin (Humulin-R), intranasal route",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":745,"activeCount":77},[],{"trials":747,"activeCount":77},[],{"trials":749,"activeCount":77},[750],{"nctId":751,"briefTitle":752,"status":396,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT04028960","IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase",[67],"2020-04-08","2019-10-23",4,[758],"Type1diabetes",[742],{"trials":761,"activeCount":77},[],{"trials":763,"activeCount":77},[],{"trials":765,"activeCount":77},[],{"intervention":767,"totalTrials":73,"cells":768},"Colchicine 0.6 mg",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":770,"activeCount":77},[],{"trials":772,"activeCount":77},[],{"trials":774,"activeCount":77},[775],{"nctId":776,"briefTitle":777,"status":229,"phases":778,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT04756128","Impact of Colchicine and Low-dose Naltrexone on COVID-19",[67],"2021-11-26","2021-12-12","2021-01-25",142,[784],"Covid19",[767,786],"Naltrexone",{"trials":788,"activeCount":77},[],{"trials":790,"activeCount":77},[],{"trials":792,"activeCount":77},[],{"intervention":786,"totalTrials":73,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":796,"activeCount":77},[],{"trials":798,"activeCount":77},[],{"trials":800,"activeCount":77},[801],{"nctId":776,"briefTitle":777,"status":229,"phases":802,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":803,"interventions":804},[67],[784],[767,786],{"trials":806,"activeCount":77},[],{"trials":808,"activeCount":77},[],{"trials":810,"activeCount":77},[],{"intervention":812,"totalTrials":9,"cells":813},"Low Dose Regular insulin",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":815,"activeCount":77},[],{"trials":817,"activeCount":77},[818,828],{"nctId":819,"briefTitle":820,"status":274,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":77,"conditions":824,"interventions":826},"NCT06434038","Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age",[66],"2026-02-28","2025-08-30",[825],"Healthy",[812,827],"High Dose Regular insulin",{"nctId":829,"briefTitle":830,"status":396,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":9,"conditions":834,"interventions":835},"NCT05866367","Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose",[66],"2024-06-28","2023-08-16",[825],[836,837],"Low dose Regular Insulin","High dose Regular insulin",{"trials":839,"activeCount":77},[],{"trials":841,"activeCount":77},[],{"trials":843,"activeCount":77},[],{"trials":845,"activeCount":77},[],{"intervention":827,"totalTrials":9,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":849,"activeCount":77},[],{"trials":851,"activeCount":77},[852,856],{"nctId":819,"briefTitle":820,"status":274,"phases":853,"primaryCompletion":822,"completion":822,"start":823,"enrollment":77,"conditions":854,"interventions":855},[66],[825],[812,827],{"nctId":829,"briefTitle":830,"status":396,"phases":857,"primaryCompletion":832,"completion":832,"start":833,"enrollment":9,"conditions":858,"interventions":859},[66],[825],[836,837],{"trials":861,"activeCount":77},[],{"trials":863,"activeCount":77},[],{"trials":865,"activeCount":77},[],{"trials":867,"activeCount":77},[],{"intervention":869,"totalTrials":73,"cells":870},"Topotecan",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":872,"activeCount":77},[],{"trials":874,"activeCount":77},[875],{"nctId":876,"briefTitle":877,"status":229,"phases":878,"primaryCompletion":879,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":885},"NCT00466232","Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer",[66],"2009-12","2010-03","2007-04",16,[884,89],"Small Cell Carcinoma",[869,886],"Sorafenib",{"trials":888,"activeCount":77},[],{"trials":890,"activeCount":77},[],{"trials":892,"activeCount":77},[],{"trials":894,"activeCount":77},[],{"intervention":886,"totalTrials":73,"cells":896},{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":905,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":898,"activeCount":77},[],{"trials":900,"activeCount":77},[901],{"nctId":876,"briefTitle":877,"status":229,"phases":902,"primaryCompletion":879,"completion":880,"start":881,"enrollment":882,"conditions":903,"interventions":904},[66],[884,89],[869,886],{"trials":906,"activeCount":77},[],{"trials":908,"activeCount":77},[],{"trials":910,"activeCount":77},[],{"trials":912,"activeCount":77},[],{"intervention":914,"totalTrials":73,"cells":915},"Zolpidem",{"EARLY_PHASE1":916,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":917,"activeCount":77},[918],{"nctId":919,"briefTitle":920,"status":229,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT04102345","Lavender vs Zolpidem Sleep Quality During Diagnostic PSG",[65],"2020-11-10","2019-09-04",58,[926],"Sleep",[914],{"trials":929,"activeCount":77},[],{"trials":931,"activeCount":77},[],{"trials":933,"activeCount":77},[],{"trials":935,"activeCount":77},[],{"trials":937,"activeCount":77},[],{"intervention":939,"totalTrials":9,"cells":940},"Insulin Glargine",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":942,"activeCount":77},[],{"trials":944,"activeCount":77},[],{"trials":946,"activeCount":77},[947],{"nctId":948,"briefTitle":949,"status":396,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":21,"conditions":953,"interventions":955},"NCT06007508","Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis",[67],"2023-02-28","2022-05-31",[954],"DKA",[939],{"trials":957,"activeCount":77},[],{"trials":959,"activeCount":77},[],{"trials":961,"activeCount":77},[962],{"nctId":963,"briefTitle":964,"status":229,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":970},"NCT01089569","Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine",[70],"2013-05","2010-04",60,[15],[971,939],"Exenatide",{"intervention":971,"totalTrials":73,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":975,"activeCount":77},[],{"trials":977,"activeCount":77},[],{"trials":979,"activeCount":77},[],{"trials":981,"activeCount":77},[],{"trials":983,"activeCount":77},[],{"trials":985,"activeCount":77},[986],{"nctId":963,"briefTitle":964,"status":229,"phases":987,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":988,"interventions":989},[70],[15],[971,939],{"intervention":991,"totalTrials":73,"cells":992},"Botulinum Toxin Type A",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":994,"activeCount":77},[],{"trials":996,"activeCount":77},[],{"trials":998,"activeCount":77},[],{"trials":1000,"activeCount":77},[],{"trials":1002,"activeCount":77},[],{"trials":1004,"activeCount":77},[1005],{"nctId":1006,"briefTitle":1007,"status":396,"phases":1008,"primaryCompletion":967,"completion":967,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},"NCT00850421","Pilot Study of BOTOX for Migraine Headaches",[70],"2004-04",35,[1012],"Migraine Headache",[991],{"intervention":1015,"totalTrials":73,"cells":1016},"Alpelisib",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1018,"activeCount":77},[],{"trials":1020,"activeCount":77},[],{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[],{"trials":1026,"activeCount":77},[],{"trials":1028,"activeCount":77},[1029],{"nctId":1030,"briefTitle":1031,"status":229,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":21,"conditions":1036,"interventions":1038},"NCT06083038","Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib",[],"2025-01-13","2026-04-21","2023-10-05",[1037],"Metastatic Breast Cancer",[1015]]